The Program Committee will identify themes and choose 4 to 5 poster abstracts to merge into hour-long discussions on select topics. A discussant (Themed Discussion moderator) will provide a 5-minute introduction outlining the state of the topic field, and then each presenter will give a brief overview of his or her poster (5 minutes) to summarize noteworthy results, conclusions, and discussion points. Discussants will interact with audience members and presenters to create a discussion that synthesizes the relevant information, covers key points of agreement and controversy, and draws comparisons to related work in the scientific field. The discussant will also provide a 5-minute conclusion summarizing key information of the session and posing important questions for future research.
Updated for CROI 2018. Presentations from randomized trials and cohorts should follow the ICMJE guidelines, including reporting of study designs (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables. See: ICMJE Preparing for Submission.
Of particular note, please consider whether there is substantive evidence of differences in effect by sex or other key demographic groups. If so, a stratified analysis should be made available during the presentation of the abstract at CROI. Please also note whether the study is ongoing or completed and whether the results are preliminary or final.
Presentation Length and Format
Themed discussion presenters (4 to 5 per themed discussion) will each be allocated 5 minutes to provide a brief overview of their posters. This time should be used to summarize key results, conclusions, and discussion points. If a discussant runs over the time limit, the moderator will interrupt and ask to have the presentation concluded.
Presenters should prepare no more than 5 content slides (the 5 slide limit is strictly enforced). CROI will provide a title slide with disclosure information for each presenter based on the information that was submitted with the abstract. The content slides should give an overview of the research with conclusions and future research direction. Do not include overly technical graphs or heavy text. If the presenter is using slides that build content from slide to slide, each additional build is considered as a separate slide and counts towards the strict limit of 5 slides. Animation (for production purposes is defined as a slide with embedded video or other movement within a single slide) are discouraged but if the presenter thinks that animation is essential to the presentation, the animation must be kept to less than 30 seconds. When submitting slides in the Speaker Ready Room at CROI, speakers should confirm that the animation works correctly. Presenters should share their slides with the Themed Discussion leader in advance of the session.
CROI will support MS PowerPoint or Apple Keynote only. Please ensure that all presentations are in one of these supported formats. High definition (HD) projectors will be used for all CROI sessions. Please apply widescreen formatting when preparing your slides (aspect ratio 16:9; resolution 1920 x 1080).
Themed Discussion participants must bring their slides on a portable drive to the Speaker Ready Room so slides can be uploaded to the presentation computer. All presenters should bring their slides to the Speaker Ready Room at least 24 hours in advance of their presentation.
A slide that lists all financial relationships with commercial entities (eg, pharmaceutical and diagnostic companies, etc) will be prepared by CROI for each presenter. This disclosure slide will be based on the information submitted by the presenter during abstract submission. If a presenter does not have any financial relationships with commercial entities to disclose, the slide will read:
Dr. [insert presenting author’s name] has no financial relationships with commercial entities to disclose.
Samples of wording of financial disclosure slide:
- Sample 1: Dr [presenting author’s name] has served as a member of data monitoring committees for Company A [company name]–sponsored clinical trials.
- Sample 2: Dr [presenting author’s name] received research grants awarded to his institution from Company A [company name] and Company B [company name], has served as a consultant to Company C [company name], and owns stock in Company D [company name].
- Sample 3: Dr [presenting author’s name] is an employee of Company E [company name].